Skip to main content

Table 1 Characteristics of the studied patients subdivided into Survivors and Nonsurvivors at discharge from ICU

From: Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients

 

All patients (355)

Survivors (248)

Nonsurvivors (107)

p Value

Age (years)

68 (57-74)

68 (57–74)

70 (58–76)

0.27

Sex

   

0.197

 Female

151 (42.54%)

111 (44.8%)

40 (37.4%)

 

 Male

204 (57.46%)

137 (55.2%)

67 (62.6%)

 

SAPS II

53 (45–62)

51 (43–58)

57 (49–69)

< 0.001

SOFA D1

11 (9–13)

10 (8–12)

12 (11–14)

< 0.001

Murray Lung Injury Score

3 (1–5)

3 (1–5)

4 (3–6)

< 0.001

Type of admission

   

0.052

 Surgical

264 (74.8%)

192 (77.7%)

77 (67.9%)

 

 Medical

89 (25.2%)

55 (22.3%)

34 (32.1%)

 

Onset of septic shock

   

0.08

 Extra ICU

265 (75.07%)

179 (72.5%)

86 (81.1%)

 

 Intra-ICU

88 (24.93%)

68 (27.5%)

20 (18.9%)

 

Primary site of infection

   

< 0.001

 Abdomen

198 (55.77%)

150 (60.5%)

48 (44.9%)

p = 0.006

 Skin

27 (7.61%)

15 (6.0%)

12 (11.2%)

 

 Bloodstream

11 (3.1%)

6 (2.4%)

5 (4.7%)

 

 Not identified

19 (5.35%)

11 (4.4%)

8 (7.5%)

 

 Lungs

64 (18.03%)

33 (13.3%)

31 (29.0%)

p < 0.001

 Urinary tract

31 (8.73%)

28 (11.3%)

3 (2.8%)

p = 0.018

 Central nervous system

5 (1.41%)

5 (2.0%)

0 (0.0%)

 

Adequacy of antimicrobial therapy

   

0.26

 No

45 (17%)

28 (15%)

17 (21%)

 

 Yes

219 (83%)

155 (84%)

64 (79%)

 

MDR bacteria

   

0.01

 Absent

277 (85.76%)

202 (89%)

75 (78.1%)

 

 Present

46 (14.24%)

25 (11%)

21 (21.9%)

 

Fungi

   

0.014

 Absent

262 (81.11%)

192 (84.6%)

70 (72.9%)

 

 Present

61 (18.89%)

35 (15.4%)

26 (27.1%)

 

Length of stay (days)

10 (6–17)

11 (6–17)

9 (3–17)

0.019

Year of enrollment

2011 (2008–2013)

2011 (2008–2013)

2011 (2008–2013)

0.57

Delay in ivIgGAM administration from admission in ICU (hours)

12 (3–39)

12 (3–33)

14 (3–66)

0.22

  1. Variables are medians (interquartile range) or absolute frequencies (relative frequencies)
  2. ivIgGAM Intravenous IgM- and IgA-enriched immunoglobulins; ICU intensive care unit; MDR multidrug resistant; SAPS II Simplified Acute Physiology Score; SOFA D1, sequential organ failure assessment calculated the first day of administration of ivIgGAM